<?xml version="1.0" encoding="UTF-8"?>
<Progress_Report_Checklist
><Grant_Information
><RFA_Number
>06-01</RFA_Number
><Grant_Number
>RS1-00409-1</Grant_Number
><Reporting_Period_Start
>8/1/2008</Reporting_Period_Start
><Reporting_Period_End
>7/31/2009</Reporting_Period_End
><Institution_Name
>University of California, Irvine</Institution_Name
><Primary_Investigator
><Prefix
/><First_Name
>Thomas</First_Name
><Middle_Name
/><Last_Name
>Lane</Last_Name
><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
/><Telephone_Number
/><Extension
/><Fax_Number
/></Primary_Investigator
></Grant_Information
><Reviewer_Information
><Grants_Manager
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>dkearney</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Grants_Manager
><Science_Officer
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>stalib</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Science_Officer
></Reviewer_Information
><Reviews
><Budget_Review
><IsRequired
/><Grant_Manager_Notes
>Award fully expended (overspent by $823).</Grant_Manager_Notes
><Science_Officer_Notes
>See GM's note</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Budget_Review
><California_Supplier_Review
><IsRequired
/><Grant_Manager_Notes
>&lt;50% CA suppliers reported. Justification is the CA suppliers used in the past raised their prices and were no longer price effective.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
/><IsComplete
/></California_Supplier_Review
><Key_Personnel_Review
><IsRequired
/><Grant_Manager_Notes
/><Science_Officer_Notes
>Adequate resources utilized. PI = 15%; Graduate student = 10%; Post doctoral fellow = 57%</Science_Officer_Notes
><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Key_Personnel_Review
><IACUC_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>Protocol Number 2010-2943 covers 08/12/10 - 8/11/11. There is a note indicating that the protocol has been revised with a change in PI to Dr. Lane. The previous protocol expired 04/16/2010. Will email asking for explanation of gap. UPDATE: protocol 2000-2168 (PI Keirstead) submitted covering gap period.</Grant_Manager_Notes
><Science_Officer_Notes
>see GM note</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></IACUC_Assurances_Review
><IRB_Assurances_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></IRB_Assurances_Review
><SCRO_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>No SCRO submitted. Previous SCRO expired March 11, 2010. Email asking for explanation. UPDATE 12/08/10: SCRO letter submitted covering to 03/11/2011.</Grant_Manager_Notes
><Science_Officer_Notes
>O.K.</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></SCRO_Assurances_Review
><Publication_Reporting_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>Two publications disclosures were uploaded with the Progress Report.</Grant_Manager_Notes
><Science_Officer_Notes
>O.K.</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Publication_Reporting_Review
><Invention_Licensing_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Invention_Licensing_Review
><PI_Effort_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
>O.K.</Science_Officer_Notes
><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/><Total_Current_Effort
>67</Total_Current_Effort
><CIRM_Award_Effort
>15</CIRM_Award_Effort
></PI_Effort_Review
></Reviews
><Award_Conditions
><Conditions_Exist
>0</Conditions_Exist
><Conditions_Met
><Conditions_Met
/><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></Conditions_Met
><New_Conditions
><New_Conditions
>0</New_Conditions
><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>1</Science_Officer_Approval
></New_Conditions
></Award_Conditions
><Prior_Approval
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Prior_Approval
><OtherIssues
/><Evaluation
><Overall_Rating
>Satisfactory</Overall_Rating
><Translational_Status
>No substantial change, incremental, or N/A</Translational_Status
><Executive_Summary
>During the NCE period PI has further confirmed the CXCL12-induced migration of hESC-derived OPCs they have further shown that CXCR2 signalling protects OPCs against IFN-g/CXCL10-mediated apoptosis. These studies were done in vitro as well as in in vivo mouse model by blocking Ab specific for CXCR2. Collectively these findings illustrate a previously unknown pathway by which cells of an Oligodendrocyte lineage protect themselves from cytokine/chemocyne-mediated death. Results of this study were published  in Proc. Natl. Acad Sci (2010)107, 11068.</Executive_Summary
></Evaluation
><Strategic_Outcome
><Five_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_1
><Five_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_2
><Five_Year_Goal_3
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_3
><Five_Year_Goal_4
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_4
><Five_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_5
><Five_Year_Goal_6
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_6
><Five_Year_Goal_8
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_8
><Ten_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_1
><Ten_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_2
><Ten_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_5
><Ten_Year_Goal_7
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_7
><Ten_Year_Goal_8
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>Contribute to basic understanding of hESC-derived OPC trafficking and survival in virus induced MS model</Outcomes
><Impact_Factor
>2</Impact_Factor
></Ten_Year_Goal_8
><Ten_Year_Goal_9a
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9a
><Ten_Year_Goal_9b
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9b
><Ten_Year_Goal_10
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_10
><OtherOutcomes
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></OtherOutcomes
></Strategic_Outcome
><IsComplete
/></Progress_Report_Checklist
>